| Literature DB >> 28805348 |
Héctor Raúl Ibarra-Sifuentes1,2, Ángel Del Cueto-Aguilera1, Daniel Alberto Gallegos-Arguijo1, Sergio Andres Castillo-Torres1, Raymundo Vera-Pineda1, Rolando Jacob Martínez-Granados1, Alexandro Atilano-Díaz1, Jesus Eduardo Cuellar-Monterrubio1, Cesar Octaviano Pezina-Cantú1, Edgar de Jesús Martínez-Guevara1, Juan Francisco Ortiz-Treviño1, Guillermo Rubén Delgado-García1, José Guadalupe Martínez-Jiménez1,2, Jesús Cruz-Valdez1,2, Concepción Sánchez-Martínez1,2.
Abstract
Intradialytic hypotension is common complication in stage 5 chronic kidney disease patients on hemodialysis. Incidence ranges from 15 to 30%. These patients have levocarnitine deficiency. A randomized, placebo-controlled quadruple-blinded trial was designed to demonstrate the levocarnitine efficiency on intradialytic hypotension prevention. Patients were randomized into four groups, to receive levocarnitine or placebo. During the intervention period, levocarnitine and placebo was administered 0 and 30 min before each hemodialysis session, respectively. During the trial, 33 patients received 1188 hemodialysis sessions. We identified 239 (21.3%) intradialytic hypotension episodes. The intradialytic hypotension episodes were less frequent in the levocarnitine group (9.3%, 60 IH events) (P < 0.001). Hemodialysis is frequently perplexed by intradialytic hypotension episodes. Levocarnitine supplementation before each hemodialysis session efficiently diminishes the intradialytic hypotension episodes. This is a new application method that must be considered and explored.Entities:
Keywords: Carnitine; Chronic kidney disease; Hemodialysis; Intradialytic hypotension
Mesh：
Substances：
Year: 2017 PMID： 28805348 DOI： 10.1111/1744-9987.12553
Source DB: PubMed Journal: Ther Apher Dial ISSN： 1744-9979 Impact factor: 1.762